Coverage
-
April 07, 2015
Boehringer Ingelheim Pharmaceuticals Inc. asked the D.C. Circuit on Monday for another shot at defending a lower court order that largely rejected the Federal Trade Commission's documents request in its investigation into an alleged Aggrenox pay-for-delay deal, arguing the circuit court's ruling slashed work product protections.
1 other articles on this case.
View all »